🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

ALNY ALNY

Company Profile ↓
$228.72
-45.49% 1Y
P/E98.16
52W High$491.22
52W Low$205.48
EPS (TTM)$2.33

Company Overview

ALNY (ALNY) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 39.8%, reflecting efficient use of shareholder capital.

Steady Revenue Expansion

Revenue has grown at a 35.6% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $3.71B (+65.2% YoY); net profit $313.75M.
  • Trailing 12 Months Year-on-year growth — revenue +65.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 35.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:35.59%
1 Year:65.19%

Stock Price Performance

1 Year:-45.49%
6 Months:-34.99%
3 Months:-24.04%
1 Month:-28.88%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 8% of range
$205.48 $491.22
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)35.86 · Neutral
Price Performance
1M-28.88%
3M-24.04%
6M-34.99%
1Y-45.49%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 39.8%.
  • Compounding revenue at 35.6% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading at a high P/E of 98.2.
  • Trading 53.4% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
98.16
Industry PE
-
Forward P/E est.
59.42
PEG Ratio
-
Book Value
$-
Price to Book
-
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
35.59%
Profit 5Y
-
Revenue (YoY)
65.19%
Earnings (YoY)
-

Profitability & Returns

ROCE
14.33%
ROE
39.76%
ROA
6.32%
Profit Margin
8.45%
Op Margin
13.51%
Gross Margin
81.64%
EPS (Latest Qtr)
$1.21
EPS (TTM)
$2.33

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
-
Current Ratio
-
Debt
-
Total Assets
$5.56B
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
0.18%
Chg in Prom Hold
-
FII / Inst Holding
101.95%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$3.71B
EBITDA
$631.44M
Free Cash Flow
$465.38M
Operating Cash Flow
$524.08M
Shares Outstanding
-
Gross Margin
81.64%
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue -------18.96M15.93M17.10M37.92M21.90M29.91M2.07M21.03M33.29M44.71M70.06M71.68M99.48M103.96M125.85M163.56M177.57M220.55M-213.26M224.82M264.31M319.29M318.75M750.53M494.33M659.83M500.92M594.19M773.69M1.25B-1.29B
Operating Income -72.94M-78.33M--110.03M-92.45M-106.68M--106.51M-120.47M-125.80M--147.41M-192.35M-254.56M--188.79M-236.27M-216.30M--210.16M-198.86M-225.20M--186.25M-146.16M-181.68M-146.73M-191.69M-258.04M-149.81M-229.83M213.87M-43.44M48.61M-76.91M18.08M-16.20M367.98M-231.44M
Net Income -71.78M-76.79M-90.72M-102.97M-90.13M-104.07M-112.93M-107.29M-118.42M-122.94M-142.23M-141.21M-163.56M-245.28M-211.44M-181.91M-219.48M-208.53M-276.19M-182.22M-179.23M-253.29M-243.54M-200.29M-189.56M-204.51M-240.34M-277.40M-405.92M-174.10M-276.02M147.75M-65.94M-16.89M-111.57M-18.25M-72.23M251.08M205.99M164.49M
Diluted EPS ---------------------1.56-2.18--1.71-1.61-1.72-2.00-2.29-3.32-1.40-2.211.15-0.52-0.13-0.87-0.14-0.551.84-1.21
R&D Expense 67.01M68.62M-96.27M83.17M97.94M-86.98M90.63M95.25M-96.86M137.58M139.94M-129.13M163.89M160.80M-169.57M155.00M161.78M-185.90M182.63M194.57M169.89M205.71M245.37M230.57M248.53M253.18M261.00M294.14M270.93M265.12M323.62M358.81M-413.13M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 96.16M100.53M100.04M-----47.16M89.91M74.91M219.75M492.85M844.29M1.04B1.83B2.25B3.71B
Cost of Revenue --------------168.82M310.41M323.37M681.87M
Gross Profit --------------868.60M1.52B1.92B3.03B
Operating Expenses --------------1.65B1.80B2.10B2.53B
Operating Income -27.84M-48.11M-44.07M-54.82M-129.46M-92.94M-404.98M-296.01M-424.59M-500.09M-814.67M-939.43M-828.44M-708.65M-785.07M-282.18M-176.88M501.58M
EBITDA ---------------926.56M-258.24M-178.85M631.44M
Interest Expense --------------155.97M121.22M141.86M252.63M
Pretax Income ---------------1.13B-433.52M-377.38M323.15M
Tax Provision --------------4.16M6.72M-99.22M9.40M
Net Income -26.25M-47.59M-43.52M-57.65M-106.01M-89.22M-360.39M-290.07M-410.11M-490.87M-761.50M-886.12M-858.28M-852.82M-1.13B-440.24M-278.16M313.75M
Diluted EPS ------------8.11-7.46-7.20-9.30-3.52-2.182.33
R&D Expense 96.88M108.73M106.38M99.30M86.57M112.96M190.25M276.50M382.39M390.63M505.42M655.11M654.82M792.16M883.01M1.00B1.13B1.32B

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --481.38M393.26M281.92M287.52M420.53M1.08B1.39B1.26B1.99B1.57B2.40B3.41B3.64B3.55B3.83B4.24B4.97B
Total Equity 199.17M202.12M177.97M158.23M118.00M134.05M270.35M936.27M1.26B920.22M1.77B1.30B1.44B1.02B588.20M-158.22M-220.64M67.09M789.18M
Cash & Equivalents 105.16M191.79M137.47M74.60M70.23M51.41M53.17M75.18M180.90M193.62M645.36M420.15M547.18M496.58M819.98M866.39M812.69M966.43M1.66B
Total Liabilities --303.42M235.03M163.92M153.47M150.18M143.33M121.80M342.59M228.30M272.84M956.44M2.39B3.06B3.70B4.05B4.17B4.18B
Current Liabilities --110.73M102.05M80.99M48.34M53.86M95.33M62.10M131.70M144.25M179.49M352.59M585.27M695.71M767.91M967.79M1.19B1.47B

Cash Flows (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 65.49M-72.14M-84.34M-87.07M-115.61M-68.66M---307.70M-382.79M-562.62M-278.43M-614.96M-641.69M-541.27M104.16M-8.31M524.08M
Investing Cash Flow 17.94M14.43M17.84M81.96M3.37M-130.50M--142.59M-290.36M272.94M-417.68M-435.52M-273.30M169.35M-336.35M-116.84M436.33M
Financing Cash Flow 3.15M3.51M3.66M738.00K93.41M200.93M--177.83M1.12B65.47M823.18M994.98M1.25B425.75M172.13M294.16M-305.19M
Capital Expenditure -10.76M-4.95M-4.73M-1.29M-8.35M-4.01M-8.96M-12.95M-64.56M-104.21M-126.89M-140.16M-70.36M-76.37M-72.06M-62.21M-34.28M-58.70M
Free Cash Flow 54.73M-77.09M-89.07M-88.36M-123.96M-72.66M---372.26M-487.00M-689.50M-418.58M-685.32M-718.07M-613.33M41.95M-42.59M465.38M

Ratios (Annual)

Figures in %.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % --------------83.7%83.0%85.6%81.6%
Operating Margin % -28.9%-47.9%-44.1%------900.3%-556.2%-1,087.6%-427.5%-168.1%-83.9%-75.7%-15.4%-7.9%13.5%
Net Margin % -27.3%-47.3%-43.5%------869.6%-545.9%-1,016.6%-403.2%-174.1%-101.0%-109.0%-24.1%-12.4%8.4%
ROE % -13.0%-26.7%-27.5%-48.9%-79.1%-33.0%-38.5%-22.9%-44.6%-27.8%-58.5%-61.6%-84.5%-145.0%714.9%199.5%-414.6%39.8%
ROCE % --13.0%-15.1%-27.3%-54.1%-25.3%-41.1%-22.4%-37.5%-27.0%-58.4%-46.0%-29.4%-24.0%-28.3%-9.9%-5.8%14.3%

Shareholding Pattern

Insiders
0.18%
Institutions
101.95%
Public Float
102.14%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ALNY

Google News Fri, 31 Jul 2026

ALNY Stock Tanks 28% as Q2 Earnings Miss Estimates, '26 Sales View Cut - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxQYkM0bXFDY3FLb0N2V2JZZVpKSVhienJuYkVlb3JIOHUxTGxkZWNMNjVBZGtEN1NtZ1FJN1FXZnNaU1hZbUlmeWlUS1plSG40MG9jYnZOb2VWbkFibWFqdDFTa0wzZ1ZydjJWYV9aQy04MUdETmh6SHQ4QTlsQ3dqTFZZVmdHZHVyMzdz?o…

Google News Fri, 31 Jul 2026

Alnylam (ALNY) Stock Stalls As TTR Sales Top $1b And Guidance Tightens - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxQSXpmdzZnZ0VTQnJ1eWFlM0syMjhqeE1CYy1JVlhfTkQtTE12LWxKc3JudnlCNUl4OFBodF9KazdCd2dneVFvb2JWMXVUd3VhNktyMEFWZHV3cDd4akk2Zm1pVGprVlVXWEd2UnFtaVFBSTVxcG9SbGttWVI2Vk5nX0UzWG5vTWZrWGExYW…

Google News Mon, 03 Aug 2026

Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: 87.96% Potential Upside Beckons Investors - DirectorsTalk Interviews

<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxQXy1fQ01DLXZjaFFZZTJkOWhRRU1TU0VBZmNoYUppVWY2OHlkUDJ1UXYwd1lpQ2JBYS1BOTI1YXVqZjJBREllbkJoc3dyUzNaNURRWHNPc3d4NUVkb0pxT3VKUFZVbktORVlPTDY3QjBMRjNFS3NveExIWVQ2UDUxVVFvbWE0dFlXSUJlTm…

Google News Mon, 03 Aug 2026

Alnylam Rises as Investors Reassess Sharp Post-Earnings Pullback - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPQjUxRDZFYS01d2JzdXlHOXZKWXdpRllXWGpmUjdNZ0F4eGFFdjBNUUFid1Q5ZTVDWGNRZjN0VmpuR013TFNTa1N2cWV3enJ2VGdJV3FiT0xGR0IzRVMyRjhNZkI5dHQyaDh1YjhaeDE2Q2ZaUFNiM2VPMVF2em5qZmEwamREOW1TaDJOX0…

Google News hu, 30 Jul 2026

Alnylam stock drops after 2026 guidance cut (ALNY:NASDAQ) - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxQVHdrY2V4QlpjREhJblJaamlwSWh4SmdNRERlc2MyV3paajZpaTQ1LU9SUktrcUhIWUF5RTAtM0FmVW55Y3ZjU25TTHBaNUpoQUxkREZ0YmdBcHk2eGg4azRMcXV2MTJVTTV0aTlrTzM5X09tNUpNcjBqNktUWFluOQ?oc=5" target="_…

Google News hu, 30 Jul 2026

Why is Alnylam Pharmaceuticals stock plunging today? - Investing.com

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxNQ0w4R0JxMDByc295YVhWN2tOTUlHTWFXU2daLVNZTHdhLU9fQWxtOW1BeDdoWkMyOWdYblJzcXNPWFNWSlJJN3VBd193Sm9VZmVuczlKYlVEc1BJQUM0UnFHYTQ1VzdySThWWUpGM1N5Sko2eG5BZlNCeXZaTkhJbFlONkdfNGpVWDhKMj…

ALNY — Frequently Asked Questions

What is the current share price of ALNY?

As of 2026-08-05 17:25 PDT, ALNY trades at $228.72 on NASDAQ/NYSE. Its 52-week range is $205.48 to $491.22.

What is the P/E ratio of ALNY?

ALNY trades at a trailing price-to-earnings (P/E) ratio of 98.16.

What is the return on equity (ROE) of ALNY?

ALNY has a return on equity (ROE) of 39.76%. Its return on capital employed (ROCE) is 14.33%.

Is ALNY a good stock to buy?

This page provides a data-driven analysis of ALNY, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space